Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases.
Nov 27 - Nov 29, 201830th Annual Piper Jaffray Healthcare Conference
Nov 9, 2018Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Oct 2, 2018
9:00 AM EDTLadenburg Thalmann 2018 Healthcare Conference